États-Unis - anglais - NLM (National Library of Medicine)

west-ward pharmaceutical corp - primidone (unii: 13afd7670q) (primidone - unii:13afd7670q) - primidone 250 mg - primidone tablets, usp used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. it may control grand mal seizures refractory to other anticonvulsant therapy. primidone is contraindicated in: - patients with porphyria and - patients who are hypersensitive to phenobarbital (see clinical pharmacology ).

États-Unis - anglais - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 100 mg - gabapentin is indicated for: - management of postherpetic neuralgia in adults - adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as gabapentin, during pregnancy. encourage women who are taking gabapentin during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling the toll free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. risk summary there are no adequate data on the developmental risks associated with the use of gabapentin in pregnant women. in nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic (increased fetal skeletal and visceral abnormalities, and increased embryofetal mortality) when administered to pregnant animals at doses similar to or lower than those used clinically [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data when pregnant mice received oral doses of gabapentin (500 mg/kg/day, 1,000 mg/kg/day, or 3,000 mg/kg/day) during the period of organogenesis, embryofetal toxicity (increased incidences of skeletal variations) was observed at the two highest doses. the no-effect dose for embryofetal developmental toxicity in mice (500 mg/kg/day) is less than the maximum recommended human dose (mrhd) of 3,600 mg/kg on a body surface area (mg/m2 ) basis. in studies in which rats received oral doses of gabapentin (500 mg/kg/day to 2,000 mg/kg/day) during pregnancy, adverse effect on offspring development (increased incidences of hydroureter and/or hydronephrosis) were observed at all doses. the lowest dose tested is similar to the mrhd on a mg/m2 basis. when pregnant rabbits were treated with gabapentin during the period of organogenesis, an increase in embryofetal mortality was observed at all doses tested (60 mg/kg, 300 mg/kg, or 1,500 mg/kg). the lowest dose tested is less than the mrhd on a mg/m2 basis. in a published study, gabapentin (400 mg/kg/day) was administered by intraperitoneal injection to neonatal mice during the first postnatal week, a period of synaptogenesis in rodents (corresponding to the last trimester of pregnancy in humans). gabapentin caused a marked decrease in neuronal synapse formation in brains of intact mice and abnormal neuronal synapse formation in a mouse model of synaptic repair. gabapentin has been shown in vitro to interfere with activity of the α2δ subunit of voltage-activated calcium channels, a receptor involved in neuronal synaptogenesis. the clinical significance of these findings is unknown. risk summary gabapentin is secreted in human milk following oral administration. the effects on the breastfed infant and on milk production are unknown. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for gabapentin and any potential adverse effects on the breastfed infant from gabapentin or from the underlying maternal condition. safety and effectiveness of gabapentin in the management of postherpetic neuralgia in pediatric patients have not been established. safety and effectiveness as adjunctive therapy in the treatment of partial seizures in pediatric patients below the age of 3 years has not been established [see clinical studies (14.2)]. the total number of patients treated with gabapentin in controlled clinical trials in patients with postherpetic neuralgia was 336, of which 102 (30%) were 65 to 74 years of age, and 168 (50%) were 75 years of age and older. there was a larger treatment effect in patients 75 years of age and older compared to younger patients who received the same dosage. since gabapentin is almost exclusively eliminated by renal excretion, the larger treatment effect observed in patients ≥75 years may be a consequence of increased gabapentin exposure for a given dose that results from an age-related decrease in renal function. however, other factors cannot be excluded. the types and incidence of adverse reactions were similar across age groups except for peripheral edema and ataxia, which tended to increase in incidence with age. clinical studies of gabapentin in epilepsy did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values in these patients [see dosage and administration (2.4), adverse reactions (6), and clinical pharmacology (12.3)]. dosage adjustment in adult patients with compromised renal function is necessary [see dosage and administration (2.3) and clinical pharmacology (12.3)]. pediatric patients with renal insufficiency have not been studied. dosage adjustment in patients undergoing hemodialysis is necessary [see dosage and administration (2.3) and clinical pharmacology (12.3)]. gabapentin is not a scheduled drug. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. gabapentin does not exhibit affinity for benzodiazepine, opioid (mu, delta or kappa), or cannabinoid 1 receptor sites. gabapentin misuse and abuse have been reported in the postmarketing setting and published literature. most of the individuals described in these reports had a history of polysubstance abuse. some of these individuals were taking higher than recommended doses of gabapentin for unapproved uses. when prescribing gabapentin, carefully evaluate patients for a history of drug abuse and observe them for signs and symptoms of gabapentin misuse or abuse (e.g., self-dose escalation and drug-seeking behavior). the abuse potential of gabapentin has not been evaluated in human studies. physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. there are rare postmarketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses of gabapentin used to treat illnesses for which the drug is not approved. such symptoms included agitation, disorientation and confusion after suddenly discontinuing gabapentin that resolved after restarting gabapentin. the dependence potential of gabapentin has not been evaluated in human studies.

États-Unis - anglais - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - nabumetone (unii: lw0tiw155z) (nabumetone - unii:lw0tiw155z) - carefully consider the potential benefits and risks of nabumetone tablets, usp and other treatment options before deciding to use nabumetone tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). nabumetone tablets, usp are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. nabumetone tablets are contraindicated in patients with known hypersensitivity to nabumetone or its excipients. nabumetone tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions , and precautions, general, preexisting asthma ). nabumetone tablets are contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings ].

États-Unis - anglais - NLM (National Library of Medicine)

tai guk pharm. co., ltd. - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - uses - helps treat and prevent diaper rash - protects chafed skin due to diaper rash and helps protect skin from wetness - helps prevent and temporarily protect chafed, chapped, cracked or windburned skin and lips do not use over deep or puncture wounds, infections or lacerations stop use and ask a doctor if condition worsens or does not improve within 7 days directions - change wet and soiled diapers promptly, cleanse the diaper area and allow to dry - apply ointment liberally as often as necessary, with each diaper change especially at bedtime or anytime when exposure to wet diapers may be prolonged

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agri west pty limited - imazapic as the ammonium salt - soluble concentrate - imazapic as the ammonium salt imidazolinone active 240.0 g/l - herbicide - peanut | prior to winter crop | sugar cane | by cultivation and/or sowing | inter-row spraying | prior to disturbance | ratoon s - awnless barnyard grass | barnyard grass or water grass | barnyard or water grass | blackberry nightshade | blue billygoat weed | boggabri weed | button grass | caltrop or yellow vine | common pigweed | common sida | cowvine | crowsfoot grass | giant or black pigweed | glossy nightshade | green amaranth | green summer grass | guinea grass | ipomoea spp. | liverseed or urochloa grass | milkweed | mintweed | native millet | nutgrass | stink grass | summer grass | amaranthus mitchellii | australian millet | barnyard grass | bellvine | bindy-eye | black nightshade | black pigweed | blowaway grass | blue salvia | blue top | bullhead | bull's head | caltrop burr | cathead | cat's-head | coast button grass | convolvulus | crab grass | dactyloctenium aegyptium | giant pigweed | goat's-head | green summergrass | liverseed grass | love grass | mexican fire plant | mint weed | paddy lucerne | paddy's lucerne | peachvine | puncture vine | salvia lanceolata | sida retusa | sida weed | star of bethlehem | tribulus maximus |

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agri west pty limited - alpha-cypermethrin; liquid hydrocarbon - emulsifiable concentrate - alpha-cypermethrin pyrethroid active 100.0 g/l; liquid hydrocarbon solvent other 735.0 g/l - insecticide - apple | apricot | banksia | broccoli | brussels sprouts | cabbage | canola oilseed crop | cauliflower | chinese cabbage | cotton - apple weevil | banksia moth - arothrophora arcuatallis | blackheaded pasture cockchafer | blue oat or pea mite | brown pasture looper | cabbage moth | cabbage white butterfly | cluster caterpillar | common armyworm - mythimna convecta | corn earworm | curculio beetle | cutworm - agrotis spp. | garden or south african vine weevil | green mirid bug | helicoverpa spp. | native budworm or bollworm | pasture webworm - hednota spp. | pea weevil | pink or brown cutworm | plague thrips | redlegged earth mite | rough bollworm | sorghum midge | southern or barley armyworm | tasmanian eucalyptus leaf beetle | tobacco budworm | tobacco looper or looper caterpillar | tomato grub | vegetable weevil | wingless grasshopper | acrossidius tasmaniae | apple weevil | banksia boring moth | barley armyworm | barley grub | brown cutworm | corn earworm | cotton bollworm | cribrate weevil | curculio beetle | desiantha weevil (wa) | diamondback moth | garden weevil | heliothis | leucania convecta | native bollworm | native budworm | p

Canada - anglais - Health Canada

bencard allergy laboratories, an allergy therapeutics (canada) ltd. company - rough pigweed; common sagebrush; lamb's quarters; western ragweed; ragweed giant; cocklebur; salvia; absinthium; russian thistle; euonymus atropurpureus - liquid - nil; nil; nil; nil; nil; nil; nil; nil; nil; nil - rough pigweed nil; common sagebrush nil; lamb's quarters nil; western ragweed nil; ragweed giant nil; cocklebur nil; salvia nil; absinthium nil; russian thistle nil; euonymus atropurpureus nil - allergenic extracts

États-Unis - anglais - NLM (National Library of Medicine)

bi-coastal pharma international llc - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - ibuprofen 400 mg - carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. ibuprofen tablets are indicated for relief of mild to moderate pain. ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. ibuprofen tablets are contraindicated in patients with known hypersensitivity to ibuprofen. ibuprofen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylact

États-Unis - anglais - NLM (National Library of Medicine)

yangzhou hongshengding chemical co.,ltd. - sodium monofluorophosphate 0.76%, anticavity toothpaste - aids in the prevention of dental cavities

États-Unis - anglais - NLM (National Library of Medicine)

qs key west aloe, llc - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm) - octinoxate 50 mg in 1 g - sunscreen - helps prevent sunburn - if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun ​stop use and ask a doctor if ​ - rash or irritation develops and lasts